Challenges and opportunities in the management of acute heart failure and cardiac amyloidosis.

Google Scholar OpenURL Placeholder Text WorldCat 13 Damy T, Zaroui A, Oghina S. The challenge of managing patients with light-chain cardiac amyloidosis: the value of cardiac magnetic resonance as a guide to the treatment response. Collaborative HF care, involving clinicians, patients, and the breadth of health system stakeholders, will optimize care and enhance guideline-directed uptake of HF therapy, which will in many cases involve the prescription of an SGLT2 inhibitor. The rate of the primary outcome was higher in PAD patients than that in non-PAD patients. Amputations, while more frequent in PAD patients, were not more common with dapagliflozin, compared with placebo, irrespective of PAD status (PAD, placebo 4.2% vs. dapagliflozin 3.7%; no PAD, placebo 0.4% vs. dapagliflozin 0.4%) ( I P i for interaction = 1.00) ( I Figure 1 i ). [Extracted from the article]